These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 14711073)

  • 1. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.
    Craig WA
    Infect Dis Clin North Am; 2003 Sep; 17(3):479-501. PubMed ID: 14711073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.
    Rayner CR; Forrest A; Meagher AK; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2003; 42(15):1411-23. PubMed ID: 14674791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
    Murillo O; Doménech A; Garcia A; Tubau F; Cabellos C; Gudiol F; Ariza J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4011-7. PubMed ID: 17015630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
    MacGowan AP
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
    Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
    Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers.
    Cai Y; Bai N; Liu X; Liang B; Wang J; Wang R
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):765-71. PubMed ID: 26227096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM; Li J; Rayner CR; Nation RL
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro.
    Sandberg A; Jensen KS; Baudoux P; Van Bambeke F; Tulkens PM; Frimodt-Møller N
    J Antimicrob Chemother; 2010 May; 65(5):962-73. PubMed ID: 20211859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of linezolid in children.
    Kaplan SL
    Pediatr Infect Dis J; 2002 Sep; 21(9):870-2. PubMed ID: 12352813
    [No Abstract]   [Full Text] [Related]  

  • 18. Linezolid: the first oxazolidinone antimicrobial.
    Moellering RC
    Ann Intern Med; 2003 Jan; 138(2):135-42. PubMed ID: 12529096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.